Multilevel analyses of on-demand medication data, with an application to the treatment of Female Sexual Interest/Arousal Disorder

被引:3
|
作者
Kessels, Rob [1 ]
Bloemers, Jos [1 ,2 ,3 ]
Tuiten, Adriaan [1 ]
van der Heijden, Peter G. M. [4 ,5 ]
机构
[1] Emot Brain BV, Almere, Flevoland, Netherlands
[2] Univ Utrecht, Utrecht Inst Pharmaceut Sci, Utrecht, Netherlands
[3] Univ Utrecht, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands
[4] Univ Utrecht, Dept Methodol & Stat, Utrecht, Netherlands
[5] Univ Southampton, Dept Social Sci, Southampton, Hants, England
来源
PLOS ONE | 2019年 / 14卷 / 08期
关键词
REFLUX SYMPTOMS; EFFICACY; MODELS; AROUSAL; SAFETY;
D O I
10.1371/journal.pone.0221063
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Data from clinical trials investigating on-demand medication often consist of an intentionally varying number of measurements per patient. These measurements are often observations of discrete events of when the medication was taken, including for example data on symptom severity. In addition to the varying number of observations between patients, the data have another important feature: they are characterized by a hierarchical structure in which the events are nested within patients. Traditionally, the observed events of patients are aggregated into means and subsequently analyzed using, for example, a repeated measures ANOVA. This procedure has drawbacks. One drawback is that these patient means have different standard errors, first, because the variance of the underlying events differs between patients and second, because the number of events per patient differs. In this paper, we argue that such data should be analyzed by applying a multilevel analysis using the individual observed events as separate nested observations. Such a multilevel approach handles this drawback and it also enables the examination of varying drug effects across patients by estimating random effects. We show how multilevel analyses can be applied to on-demand medication data from a clinical trial investigating the efficacy of a drug for women with low sexual desire. We also explore linear and quadratic time effects that can only be performed when the individual events are considered as separate observations and we discuss several important statistical topics relevant for multilevel modeling. Taken together, the use of a multilevel approach considering events as nested observations in these types of data is advocated as it is more valid and provides more information than other (traditional) methods.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Randomized crossover study investigating daily versus on-demand vulvar Visnadine spray in women affected by female sexual arousal disorder
    Caruso, Salvatore
    Mauro, Diletta
    Cariola, Maria
    Fava, Valentina
    Rapisarda, Agnese Maria Chiara
    Cianci, Antonio
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2018, 34 (02) : 110 - 114
  • [22] Damiana for the treatment of female sexual interest/arousal disorder (FSIAD) - Results of a multicentre non-interventional study
    Rotmann, R. A.
    Mordhorst, N.
    Kassen, A.
    [J]. PLANTA MEDICA, 2021, 87 (15) : 1258 - 1258
  • [23] Psychometric Properties of the Sexual Event Diary in a Sample of Dutch Women With Female Sexual Interest/Arousal Disorder
    van Nes, Yvonne
    Bloemers, Jos
    Kessels, Rob
    van der Heijden, Peter G. M.
    van Rooij, Kim
    Gerritsen, Jeroen
    DeRogatis, Leonard
    Tuiten, Adriaan
    [J]. JOURNAL OF SEXUAL MEDICINE, 2018, 15 (05): : 722 - 731
  • [24] Topical alprostadil in the treatment of female sexual arousal disorder: A pilot study
    Islam, A
    Mitchel, J
    Rosen, R
    Phillips, N
    Ayers, C
    Ferguson, D
    Yeager, J
    [J]. JOURNAL OF SEX & MARITAL THERAPY, 2001, 27 (05) : 531 - 540
  • [25] Female Sexual Arousal Disorder Sildenafil Cream as Potential Treatment in Development
    Pinkerton, JoAnn V.
    [J]. OBSTETRICS AND GYNECOLOGY, 2024, 144 (02): : 142 - 143
  • [26] Preliminary Efficacy of Topical Sildenafil Cream for the Treatment of Female Sexual Arousal Disorder
    Johnson, Isabella
    Thurman, Andrea Ries
    Cornell, Katherine A.
    Hatheway, Jessica
    Dart, Clint
    Brainard, C. Paige
    Friend, David R.
    Goldstein, Andrew
    [J]. OBSTETRICS AND GYNECOLOGY, 2024, 144 (02): : 144 - 152
  • [27] Topical alprostadil for the treatment of premenopausal women with female sexual arousal disorder (FSAD)
    Costabile, RA
    McMurray, JG
    Singh, G
    Wiatrak, M
    Peterson, C
    [J]. JOURNAL OF UROLOGY, 2005, 173 (04): : 201 - 201
  • [28] Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder
    Pryde, David C.
    Cook, Andrew S.
    Burring, Denise J.
    Jones, Lyn H.
    Foll, Stephanie
    Platts, Michelle Y.
    Sanderson, Vivienne
    Corless, Martin
    Stobie, Alan
    Middleton, Donald S.
    Foster, Laura
    Barker, Laura
    Van der Graaf, Piet
    Stacey, Peter
    Kohl, Christopher
    Coggon, Sara
    Beaumont, Kevin
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2007, 15 (01) : 142 - 159
  • [29] Mindfulness and Sex Education for Sexual Interest/Arousal Disorder: Mediators and Moderators of Treatment Outcome
    Brotto, Lori A.
    Zdaniuk, Bozena
    Chivers, Meredith L.
    Jabs, Faith
    Grabovac, Andrea D.
    Lalumiere, Martin L.
    [J]. JOURNAL OF SEX RESEARCH, 2023, 60 (04) : 508 - 521
  • [30] A PHASE 2 PROGRAM ON FEMALE SEXUAL AROUSAL DISORDER AND HYPOACTIVE SEXUAL DESIRE DISORDER: PATIENT CHARACTERISTICS AND IMPLICATIONS FOR DIAGNOSIS AND TREATMENT OF FEMALE SEXUAL DYSFUNCTION
    Althof, S.
    Kingsberg, S.
    Symons, J.
    Portman, D.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2016, 13 (06): : S244 - S245